尤瑞克林治疗59例急性脑梗死的临床疗效观察

Clinical observation on the Efficacy of Kallikrein in the Treatment of 59 Patients with Acute Cerebral Infarction

【目的】观察尤瑞克林治疗急性脑梗死的临床疗效及安全性。【方法】选择发病48h内的急性脑梗死患者117例，随机分为治疗组（59例）和对照组（58例）。对照组给予对症和支持等常规治疗，治疗组在对照组治疗的基础上加用尤瑞克林治疗0．15PNAU／d，疗程均为14d。两组于治疗前后采用神经功能缺损（NIHSS）评分量表进行神经功能缺损评定，治疗后3个月采用BI量表进行日常生活能力评定，并监测不良反应。【结果】治疗14d后NIHSS评分、3个月时BI评分及临床有效率，治疗组与对照组相比差异有显著性（P〈0．05），两组组均无明显不良反应。【结论】尤瑞克林治疗急性脑梗死安全有效，能显著改善预后。

[Objective]To evaluate the efficacy and adverse reactions of Kallikrein on acute cerebral infarction （ACI）.[Methods]A randomized controlled study was carried out, and 117 patients with ACI were en- rolled within 48 hours of onset. They were randomly allocated into treatment group （ n = 59） and control group （ n = 58）. Patients in both groups were given general supportive care. Patients in treatment group also received kallikrein injection 0. 15PNA once per day for 14 days. The neurological deficits and activities of daily living（ADL） of patients in both groups were assessed by Stroke Scale （NIHSS） and Barthel Index （BI） before and after the treatment, respectively. Clinical efficacy was evaluated according to changes of NIHSS on the 14th day and BI scores on the 90th day. [Results] There was a significant difference in NIHSS and BI scores between treatment group and control group（P〈0.05）. There was no distinct adverse reaction in two groups. [Conclusion]Kallikrein is effective and safe in treatment of patients with acute cerebral infarction. It is worthy to be recommended for clinical application.